28 search results for: biologics
When is the right time to consider a biologic in patients with CRSwNP?
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.
Urticaria Centers of Reference and Excellence (UCARE) 2023 | São Paulo
Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.
ESPGHAN 2024 | Clinical Management of Young Children With EoE
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.
ERS 2024 | IL-33 A Promising Target
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
ESPGHAN 2025 Pediatric EoE: Clinical Data & Long-Term Management
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg
Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
ESPGHAN 2024 | Clinical Management of EoE in Adolescents to Adulthood
Prof. Salvatore Oliva discusses the latest treatment options for adolescents and adults with EoE and the importance of effective transition of care.
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin
ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.
